Recent advances in the development of histamine H₃ antagonists

Bibliography

• ARRANG JM, GARBARG M, SCHWARTZ JC: Autoinhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature (1983) 302:832-837.
   PubMed Web of Science ®Google Scholar
• LOVENBERG TW, ROLAND BL, WILSON SJ et al.: Cloning and functional expression of the human histamine H3 receptor. Mol. Pharmacol. (1999) 55:1101-1107.
   PubMed Web of Science ®Google Scholar
• CELANIRE S, WIJTMANS M, TALAGA P, LEURS R, DE ESCH IJP: Histamine H3 receptor antagonists reach out for the clinic. Drug Disc. Today (2005) 10:1613-1627.
   PubMed Web of Science ®Google Scholar
• HANCOCK AA, BRUNE ME: Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists. Expert Opin. Investig. Drugs (2005) 14:223-241.
   PubMed Web of Science ®Google Scholar
• LEURS R, BAKKER RA, TIMMMERMAN H, DE ESCH IJP: The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat. Rev. Drug Disc. (2005) 4:107-120.
   PubMed Web of Science ®Google Scholar
• BONGERS G, BAKKER RA, LEURS R: Molecular aspects of the histamine H3 receptor. Bio. Pharmacol. (2007) 73:1195-1204.
   PubMed Web of Science ®Google Scholar
• ASLANIAN R, SHIH N-Y: Recent progress in histamine H3 receptor chemistry. Ann. Reports Med. Chem. (2004) 39:57-66.
   Web of Science ®Google Scholar
• VOHORA D: Histamine-selective H3 receptor ligands and cognitive functions: an overview. IDrugs (2004) 7:667-673.
   PubMed Web of Science ®Google Scholar
• PASSANI MB, LIN J-S, HANCOCK A, CROCHET S, BLANDINA P: The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol. Sci. (2004) 25:618-625.
   PubMed Web of Science ®Google Scholar
• HANCOCK AA, FOX GB: Perspectives on cognitive domains, H3 receptor ligands and neurological disease. Expert Opin. Investig. Drugs (2004) 13:1237-1248.
   PubMed Web of Science ®Google Scholar
• HOWARD HR: Agents for attention-deficit hyperactivity disorder - an update. Expert Opin. Ther. Patents (2004) 14:983-1008.
   Web of Science ®Google Scholar
• HANCOCK AA: H3 receptor antagonists/inverse agonists as anti-obesity agents. Curr. Opin. Investig. Drugs (2003) 4(10):1190-1197.
   PubMedGoogle Scholar
• STARK H: Recent advances in histamine H3/H4 receptor ligands. Expert Opin. Therap. Patents (2003) 13:851-865.
   Google Scholar
• HAAS H, PANULA P: The role of histamine and the tuberomamillary nucleus in the nervous system. Nat. Rev. Neurosci. (2003) 4:121-130.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ JC, ARRANG JM, GARBARG M, POLLARD H, RUAT M: Histaminergic transmission in the mammalian brain. Physiol. Rev. (1991) 71:1-51.
   PubMed Web of Science ®Google Scholar
• BAKKER RA: Histamine H3-receptor isoforms. Inflammation Res. (2004) 53:509-516.
   PubMed Web of Science ®Google Scholar
• ESBENSHADE TA, KRUEGER KM, YAO BB et al.: Differences in pharmacological properties of histamine H3 receptor agonists and antagonists revealed at two human H3 receptor isoforms. Inflammation Res. (2006) 55(Suppl. 1):S45-S46.
   Google Scholar
• MARTINEZ-MIR MI, POLLARD H, MOREAU J et al.: Three histamine receptors (H1, H2, and H3) visualized in the brain of human and non-human primates. Brain Res. (1990) 526:322-327.
   PubMed Web of Science ®Google Scholar
• SCHLICKER E, KATHMANN M: Modulation of in vitro neurotransmission in the CNS and in the retina via H3 heteroreceptors. In: The Histamine H₃ Receptor; a Target for New Drugs. Leurs R, Timmerman H (Eds), Elsevier (1998):13-26.
   Google Scholar
• BERTACCINI G, CORUZZI G, POLI E: Functional role of histamine H3 receptors in peripheral tissues. Pharmacochem. Library (1998) 30:59-111.
   Google Scholar
• BERLIN M, TING PC, VACCARO WD et al.: Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists. Bioorg. Med. Chem. Lett. (2006) 16:989-994.
   PubMed Web of Science ®Google Scholar
• ASLANIAN RA, ZHU X, TOM WC et al.: Benzimidazole-substituted (3-phenyoxypropyl)amines as histamine H3 antagonists. 232nd American Chemical Society National Meeting. San Fransisco, USA (2006):MEDI-501.
   Google Scholar
• ESBENSHADE TA, FOX GB, KRUEGER KM et al.: Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. J. Pharm. Exp. Ther. (2005) 313:165-175.
   PubMed Web of Science ®Google Scholar
• FOX GB, ESBENSHADE TA, PAN JB et al.: Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J. Pharm. Exp. Ther. (2005) 313:176-190.
   PubMed Web of Science ®Google Scholar
• COWART M, FAGHIH R, CURTIS MP et al.: 4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention. J. Med. Chem. (2005) 48:38-55.
   PubMed Web of Science ®Google Scholar
• COWART M, PRATT JK, STEWART AO, BENNANI YL, ESBENSHADE TA, HANCOCK AA: A new class of potent non-imidazole H3 antagonists: 2-aminoethylbenzofurans. Bioorg. Med. Chem. Lett. (2004) 14:689-693.
   PubMed Web of Science ®Google Scholar
• LIGNEAU X, PERRIN D, LANDAIS L et al.: BF2.649 [1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: preclinical pharmacology. J. Pharmacol. Exp. Ther. (2007) 320:365-375.
   PubMed Web of Science ®Google Scholar
• LIGNEAU X, LANDAIS L, PERRIN D et al.: Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. Bio. Pharmacol. (2007) 73:1215-1224.
   PubMed Web of Science ®Google Scholar
• COOPER I, ABBERLEY L, BRIGGS M et al.: Novel potent H3 antagonists: therapeutics for the treatment of dementia including Alzheimer's disease. The 19th International Symposium in Medicinal Chemistry (Part IV). Istanbul, Turkey (2006):P247.
   Google Scholar
• LIU H, ALTENBACH RJ, MILLER TR, ESBENSHADE TA, HANCOCK AA, COWART M: Design, synthesis, and structure-activity relationship of novel non-imidazole histamine H3 antagonists. 230th American Chemical Society National Meeting. Washington, USA (2005):MEDI-103.
   Google Scholar
• ALTENBACH RJ, LIU H, ESBENSHADE TA, FOX GB, HANCOCK AA, COWART M: Bicyclic heteroaromatic histamine H3 antagonists: synthesis, potency, and in vivo profiles of analogs optimized for drug-likeness. 230th American Chemical Society National Meeting. Washington, USA (2005):MEDI-102.
   Google Scholar
• HOWARD HR: Fused thiazole derivatives having affinity for the histamine H3 receptor. Expert Opin. Ther. Patents (2007) 17:129-131.
   Web of Science ®Google Scholar
• MEDHURST AD, ATKINS AR, BERESFORD IJ et al.: GSK189254 – a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J. Pharmacol. Exp. Ther., JPET Fast Forward. Published on February 27, 2007 as DOI:10.1124/jpet.107.120311.
   PubMed Web of Science ®Google Scholar
• COWART M, SUN M, ZHAO C et al.: A new family of histamine H3 receptor antagonists based on a natural product: discovery, development of SAR and properties of the series. European Histamine Research Society - 35th Annual Meeting (Part I). Delphi, Greece (2006):O-31.
   Google Scholar
• MEDHURST AD, BRIGGS MA, BRUTON G et al.: Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats. Bio. Pharmacol. (2007) 73:1182-1194.
   PubMed Web of Science ®Google Scholar
• PARMENTIER R, ANACLET C, GUHENNEC C et al.: The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Bio. Pharmacol. (2007) 73:1157-1171.
   PubMed Web of Science ®Google Scholar
• PASSANI MB, GIANNONI P, BUCHERELLI C, BALDI E, BLANDINA P: Histamine in the brain: beyond sleep and memory. Bio. Pharmacol. (2007) 73:1113-1122.
   PubMed Web of Science ®Google Scholar
• PAN JB, YAO BB, MILLER TR et al.: Evidence for tolerance following repeated dosing in rats with ciproxifan, but not with A-304121. Life Sci. (2006) 79:1366-1379.
   PubMed Web of Science ®Google Scholar
• TOKITA S, TAKAHASHI K, KOTANI H: Recent advances in molecular pharmacology of the histamine systems: physiology and pharmacology of histamine H3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders. J. Pharmacol. Sci. (2006) 101:12-18.
   PubMed Web of Science ®Google Scholar
• HANCOCK AA, BITNER RS, KRUEGER KM et al.: Distinctions and contradistinctions between antiobesity histamine H3 receptor (H3R) antagonists compared to cognition-enhancing H3 receptor antagonists. Inflammation Res. (2006) 55(Suppl. 1):S42-S44.
   Google Scholar
• YOSHIMOTO R, MIYAMOTO Y, SHIMAMURA K et al.: Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus. Proc. Natl. Acad. Sci. USA (2006) 103:13866-13871.
   PubMed Web of Science ®Google Scholar
• NORMAN P: A H3 antagonist for treating allergic rhinitis: a development candidate? Expert Opin. Ther. Patents (2007) 17(4):449-452.
   Web of Science ®Google Scholar
• FOX GB, PAN JB, RADEK RJ et al.: Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J. Pharm. Exp. Ther. (2003) 305:897-908.
   PubMed Web of Science ®Google Scholar
• ESBENSHADE TA, FOX GB, KRUEGER KM et al.: Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. Biochem. Pharmacol. (2004) 68:933-945.
   PubMed Web of Science ®Google Scholar